Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.

Camp NJ, Madsen MJ, Herranz J, Rodríguez-Lescure Á, Ruiz A, Martín M, Bernard PS.

Breast Cancer Res Treat. 2019 Jan 23. doi: 10.1007/s10549-018-05097-5. [Epub ahead of print]

PMID:
30673970
2.

Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.

Gulbahce HE, Bernard PS, Weltzien EK, Factor RE, Kushi LH, Caan BJ, Sweeney C.

Cancer. 2018 Dec 15;124(24):4676-4684. doi: 10.1002/cncr.31776. Epub 2018 Oct 12.

PMID:
30311638
3.

Membrane proteins significantly restrict exosome mobility.

Skliar M, Chernyshev VS, Belnap DM, Sergey GV, Al-Hakami SM, Bernard PS, Stijleman IJ, Rachamadugu R.

Biochem Biophys Res Commun. 2018 Jul 2;501(4):1055-1059. doi: 10.1016/j.bbrc.2018.05.107. Epub 2018 May 19.

PMID:
29777705
4.

Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15.

Madsen MJ, Knight S, Sweeney C, Factor R, Salama M, Stijleman IJ, Rajamanickam V, Welm BE, Arunachalam S, Jones B, Rachamadugu R, Rowe K, Cessna MH, Thomas A, Kushi LH, Caan BJ, Bernard PS, Camp NJ.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):644-652. doi: 10.1158/1055-9965.EPI-17-0887. Epub 2018 Apr 12.

PMID:
29650789
5.

Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.

Delker DA, Wood AC, Snow AK, Samadder NJ, Samowitz WS, Affolter KE, Boucher KM, Pappas LM, Stijleman IJ, Kanth P, Byrne KR, Burt RW, Bernard PS, Neklason DW.

Cancer Prev Res (Phila). 2018 Jan;11(1):4-15. doi: 10.1158/1940-6207.CAPR-17-0130. Epub 2017 Nov 6.

6.

Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.

Cespedes Feliciano EM, Kwan ML, Kushi LH, Chen WY, Weltzien EK, Castillo AL, Sweeney C, Bernard PS, Caan BJ.

Cancer. 2017 Jul 1;123(13):2535-2542. doi: 10.1002/cncr.30637. Epub 2017 Mar 13.

7.

Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies.

Jones LW, Kwan ML, Weltzien E, Chandarlapaty S, Sternfeld B, Sweeney C, Bernard PS, Castillo A, Habel LA, Kroenke CH, Langholz BM, Queensberry CP Jr, Dang C, Weigelt B, Kushi LH, Caan BJ.

Cancer Res. 2016 Sep 15;76(18):5415-22. doi: 10.1158/0008-5472.CAN-15-3307. Epub 2016 Aug 3.

8.

Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.

Asleh-Aburaya K, Sheffield BS, Kos Z, Won JR, Wang XQ, Gao D, Wolber R, Gilks CB, Bernard PS, Chia SK, Nielsen TO.

Histopathology. 2017 Jan;70(2):185-194. doi: 10.1111/his.13038. Epub 2016 Sep 29.

PMID:
27402148
9.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.

Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Weber KE, Rodriguez CA, Alvarez IM, Segui MA, Perou CM, Casas M, Carrasco E, Caballero R, Rodriguez-Lescure A.

Breast Cancer Res Treat. 2016 Feb;156(1):81-9. doi: 10.1007/s10549-016-3725-z. Epub 2016 Feb 24.

10.

Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.

Sheffield BS, Kos Z, Asleh-Aburaya K, Wang XQ, Leung S, Gao D, Won J, Chow C, Rachamadugu R, Stijleman I, Wolber R, Gilks CB, Myles N, Thomson T, Hayes MM, Bernard PS, Nielsen TO, Chia SK.

Breast Cancer Res Treat. 2016 Feb;155(3):483-90. doi: 10.1007/s10549-016-3689-z. Epub 2016 Feb 4.

PMID:
26846986
11.

Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus.

Camp NJ, Lin WY, Bigelow A, Burghel GJ, Mosbruger TL, Parry MA, Waller RG, Rigas SH, Tai PY, Berrett K, Rajamanickam V, Cosby R, Brock IW, Jones B, Connley D, Sargent R, Wang G, Factor RE, Bernard PS, Cannon-Albright L, Knight S, Abo R, Werner TL, Reed MW, Gertz J, Cox A.

Cancer Res. 2016 Apr 1;76(7):1916-25. doi: 10.1158/0008-5472.CAN-15-1629. Epub 2016 Jan 21.

12.

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).

Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT.

NPJ Breast Cancer. 2016;2. pii: 15023. doi: 10.1038/npjbcancer.2015.23. Epub 2016 Jan 6.

13.

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS.

BMC Med Genomics. 2015 Aug 22;8:54. doi: 10.1186/s12920-015-0129-6.

14.

Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival.

Kwan ML, Bernard PS, Kroenke CH, Factor RE, Habel LA, Weltzien EK, Castillo A, Gunderson EP, Maxfield KS, Stijleman IJ, Langholz BM, Quesenberry CP Jr, Kushi LH, Sweeney C, Caan BJ.

J Natl Cancer Inst. 2015 Apr 28;107(7). pii: djv087. doi: 10.1093/jnci/djv087. Print 2015 Jul.

15.

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA.

Oncologist. 2015 May;20(5):474-82. doi: 10.1634/theoncologist.2014-0372. Epub 2015 Apr 23.

16.

Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.

Kwan ML, Kroenke CH, Sweeney C, Bernard PS, Weltzien EK, Castillo A, Factor RE, Maxfield KS, Stijleman IJ, Kushi LH, Quesenberry CP Jr, Habel LA, Caan BJ.

BMC Cancer. 2015 Apr 14;15:278. doi: 10.1186/s12885-015-1263-4.

17.

Size and shape characterization of hydrated and desiccated exosomes.

Chernyshev VS, Rachamadugu R, Tseng YH, Belnap DM, Jia Y, Branch KJ, Butterfield AE, Pease LF 3rd, Bernard PS, Skliar M.

Anal Bioanal Chem. 2015 May;407(12):3285-301. doi: 10.1007/s00216-015-8535-3. Epub 2015 Mar 28.

PMID:
25821114
18.

Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models.

Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS, Stijleman IJ, Green JE, Bennett C, Juliana MM, Moeinpour F, Steele VE, Lubet RA.

Cancer Prev Res (Phila). 2015 Mar;8(3):231-9. doi: 10.1158/1940-6207.CAPR-14-0181-T. Epub 2015 Feb 13.

19.

Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.

Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, Castillo A, Bernard PS, Factor RE, Kushi LH, Caan BJ.

Breast Cancer Res Treat. 2014 Apr;144(3):689-99. doi: 10.1007/s10549-014-2899-5. Epub 2014 Mar 7.

20.

Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.

Caan BJ, Sweeney C, Habel LA, Kwan ML, Kroenke CH, Weltzien EK, Quesenberry CP Jr, Castillo A, Factor RE, Kushi LH, Bernard PS.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):725-34. doi: 10.1158/1055-9965.EPI-13-1017. Epub 2014 Feb 12.

21.

Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.

Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr, Shakespear K, Weltzien EK, Stijleman IJ, Davis CA, Ebbert MT, Castillo A, Kushi LH, Caan BJ.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):714-24. doi: 10.1158/1055-9965.EPI-13-1023. Epub 2014 Feb 12.

22.

A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.

Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, Perou CM, Bernard PS, Nielsen TO.

Mod Pathol. 2013 Nov;26(11):1438-50. doi: 10.1038/modpathol.2013.97. Epub 2013 May 24.

23.

Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens.

Wilkerson MD, Schallheim JM, Hayes DN, Roberts PJ, Bastien RR, Mullins M, Yin X, Miller CR, Thorne LB, Geiersbach KB, Muldrew KL, Funkhouser WK, Fan C, Hayward MC, Bayer S, Perou CM, Bernard PS.

J Mol Diagn. 2013 Jul;15(4):485-97. doi: 10.1016/j.jmoldx.2013.03.007. Epub 2013 May 20.

24.

Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes.

Smith BA, Shelton DN, Kieffer C, Milash B, Usary J, Perou CM, Bernard PS, Welm BE.

Genes Cancer. 2012 Sep;3(9-10):550-63. doi: 10.1177/1947601913475359.

25.

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.

Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS.

Breast Cancer Res Treat. 2013 Apr;138(2):457-66. doi: 10.1007/s10549-013-2416-2. Epub 2013 Feb 20.

26.

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM.

Breast Cancer Res Treat. 2013 Jan;137(2):483-92. doi: 10.1007/s10549-012-2378-9. Epub 2012 Dec 15.

27.

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM.

J Clin Oncol. 2013 Jan 10;31(2):203-9. doi: 10.1200/JCO.2012.43.4134. Epub 2012 Dec 10.

28.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44.

29.

A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.

Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO.

Clin Cancer Res. 2012 Aug 15;18(16):4465-72. Epub 2012 Jun 18.

30.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.

J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4.

31.

Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.

Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, Bernard PS, Perou CM, Hayes DN.

PLoS One. 2012;7(5):e36530. doi: 10.1371/journal.pone.0036530. Epub 2012 May 10.

32.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM.

Ann Oncol. 2012 Nov;23(11):2866-73. doi: 10.1093/annonc/mds080. Epub 2012 Apr 24.

33.

Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.

Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L.

Oncologist. 2012;17(4):492-8. doi: 10.1634/theoncologist.2012-0007. Epub 2012 Mar 14.

34.

Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.

Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO.

Clin Cancer Res. 2012 Apr 15;18(8):2402-12. doi: 10.1158/1078-0432.CCR-11-2956. Epub 2012 Feb 20.

35.

Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans.

Ebbert MT, Bastien RR, Boucher KM, Martín M, Carrasco E, Caballero R, Stijleman IJ, Bernard PS, Facelli JC.

J Clin Bioinforma. 2011 Dec 23;1:37. doi: 10.1186/2043-9113-1-37.

36.

TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.

Liu J, Welm B, Boucher KM, Ebbert MT, Bernard PS.

Am J Pathol. 2012 Feb;180(2):839-47. doi: 10.1016/j.ajpath.2011.10.020. Epub 2011 Dec 2.

37.

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.

DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL.

Nat Med. 2011 Oct 23;17(11):1514-20. doi: 10.1038/nm.2454.

38.

High quality and quantity Genome-wide germline genotypes from FFPE normal tissue.

Cannon-Albright LA, Cooper KG, Georgelas A, Bernard PS.

BMC Res Notes. 2011 May 26;4:159. doi: 10.1186/1756-0500-4-159.

39.

Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

Irvin WJ Jr, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC.

Clin Breast Cancer. 2010 Dec 1;10(6):465-70. doi: 10.3816/CBC.2010.n.061.

40.

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ.

Clin Cancer Res. 2010 Nov 1;16(21):5222-32. doi: 10.1158/1078-0432.CCR-10-1282. Epub 2010 Sep 13.

41.

Clinical implementation of the intrinsic subtypes of breast cancer.

Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS.

Lancet Oncol. 2010 Aug;11(8):718-9; author reply 720-1. doi: 10.1016/S1470-2045(10)70176-5. No abstract available.

PMID:
20688274
42.

Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.

Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, Bernard PS, Perou CM, Hayes DN.

Clin Cancer Res. 2010 Oct 1;16(19):4864-75. doi: 10.1158/1078-0432.CCR-10-0199. Epub 2010 Jul 19.

43.

Distribution of molecular breast cancer subtypes in middle eastern-saudi arabian women: a pilot study.

Al-Tamimi DM, Bernard PS, Shawarby MA, Al-Amri AM, Hadi MA.

Ultrastruct Pathol. 2009 Jul-Aug;33(4):141-50. doi: 10.1080/01913120903183135.

PMID:
19728229
44.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.

45.

Supervised risk predictor of breast cancer based on intrinsic subtypes.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS.

J Clin Oncol. 2009 Mar 10;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370. Epub 2009 Feb 9.

46.

ESR1 gene amplification in breast cancer: a common phenomenon?

Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K, Teschendorff AE, Quackenbush JF, Marioni JC, Leung S, Perou CM, Neilsen TO, Ellis M, Gray JW, Bernard PS, Huntsman DG, Caldas C.

Nat Genet. 2008 Jul;40(7):806-7; author reply 810-2. doi: 10.1038/ng0708-806. No abstract available.

47.

High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling.

Bastien R, Lewis TB, Hawkes JE, Quackenbush JF, Robbins TC, Palazzo J, Perou CM, Bernard PS.

Hum Mutat. 2008 May;29(5):757-64. doi: 10.1002/humu.20726.

PMID:
18348286
48.

EGFR associated expression profiles vary with breast tumor subtype.

Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM.

BMC Genomics. 2007 Jul 31;8:258.

49.

Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues.

Mullins M, Perreard L, Quackenbush JF, Gauthier N, Bayer S, Ellis M, Parker J, Perou CM, Szabo A, Bernard PS.

Clin Chem. 2007 Jul;53(7):1273-9. Epub 2007 May 24.

50.

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM.

Genome Biol. 2007;8(5):R76.

Supplemental Content

Loading ...
Support Center